Mark Budde had a problem familiar to people who work with DNA: getting it sequenced took too much time. At Caltech, he had developed research workflows that offered another way. Fifty Years saw a possible business inside that irritation. Budde joined the inaugural cohort of its founder program. The work eventually became part of Plasmidsaurus, a sequencing service whose name sounds like a dinosaur hired to check your homework.
- Fifty Years invests at pre-seed and seed, with a taste for difficult scientific problems.
- Its 5050 program helps technical people explore founding a company, without fees or an equity charge.
- The practical lesson: find a buyer and a viable cost before falling in love with an invention.
There is a tempting way to tell this story: brilliant scientist meets enlightened investor, company appears. The interesting part is messier. A workflow must become a service. Someone has to collect samples, return useful results, and persuade researchers to trust them. Scientific achievement gets the conversation started. The business has an entirely different examination to pass.
A venture firm moves upstream
Fifty Years, founded in 2015 by Ela Madej and Seth Bannon, occupies the early end of venture capital. Its investments include businesses working on chemicals, satellites, diagnostics, and laboratory automation. Solugen, Astranis, BillionToOne, and Opentrons illustrate the range. The connecting idea is that solving a consequential technical problem can also produce a valuable company.
Other deep-tech investors, including Lux Capital and DCVC, inhabit nearby territory. Programs such as IndieBio and HAX also help technical founders get started. Fifty Years’ particular combination reaches into the period before incorporation: education, grants, a public spinout guide, then potentially an investment. It gives researchers several ways to engage before they are ready to pitch.
The expertise is deliberately mixed. Partner Alex Teng has a Caltech environmental-science PhD; partner D. Scott Phoenix founded Vicarious AI. The team also includes engineering, product, talent, and design roles. In 2023, the firm staged a product launch for its support tools, including network software and an AI literature tool. A VC with a product launch: Silicon Valley does occasionally find a new joke.
Free tuition. Serious homework.
5050 is the clearest expression of this approach. The current offer is twelve weeks of workshops, partner mentorship, and cohort gatherings. Participants can begin while employed or researching. They need neither a co-founder nor a polished idea. The advertised commitment is roughly ten hours weekly, much of it spent moving an idea forward.
Participation costs nothing and takes no equity. That removes a financial decision from an already complicated career decision. It does not remove the work. The questions are commercial and personal: Is this a market worth entering? Can the technology meet the required price? Do I actually want to spend years building this?
Money enters through a separate door. Limited partners commit capital to investment funds, which acquire stakes in startups. A public Fund I filing describes management fees tied to commitments. In October 2021, Fifty Years announced a $90 million third fund backed by 44 founders of billion-dollar companies. Those founders supplied both capital and a potential reservoir of operating experience.
Distinct routes, not a compulsory sequence.
The paperwork can beat the science
The Spinout Playbook explains another reason a researcher might need help. Its authors describe technology-transfer negotiations dragging on until founders burn out, teams lose momentum, and investors leave. That is an unglamorous failure mechanism. The experiment may work perfectly while the company stalls over the right to use it.
“The team, not the invention, is the true foundation of your company.”Fifty Years · Spinout Playbook
Manifest Grants addresses a neighboring gap: the practical research needed to establish commercial potential. It offers $25,000 to $100,000, asks for applications of at most two pages, and advertises decisions within 21 days without taking IP. The grant buys room for a prototype, an economic model, or a real-world test. It cannot manufacture demand. The distinction matters to a researcher choosing a funding route: a grant can test whether a process works outside the lab, while an investor will also need a case for who pays and how the operation grows.
Plasmidsaurus makes that distinction tangible. Oxford Nanopore described more than 500 sample drop boxes worldwide in 2024, with overnight sequencing in central locations. The company was solving a recurring laboratory chore. Researchers could understand the offer without first agreeing to a grand vision of biology’s future.
Conviction needs an experiment
The UK provides a second test. Fifty Years announced its ARIA partnership in October 2024. By February 2026, the agency reported that 86 scientists and engineers had participated, creating 26 companies that collectively raised more than £7.5 million in pre-seed funding over the first fifteen months.
86 participants · over £7.5M raised
ARIA’s first 15-month report, February 2026
One participant arrived believing their idea could not attract venture backing. ARIA says technology validation, revised positioning, and experienced-founder networks helped them reach a different conclusion. They subsequently raised over £1 million. That is a useful account of changed conviction. Company formation and fundraising, however, are early results; neither proves that a business will endure.
A founder can copy the underlying discipline without joining anything. Name the customer. Find the painful workflow. Estimate the price and delivery cost. Choose an experiment that could disprove the commercial story. Then decide what the next milestone deserves: more research, a grant, or a company.
There are sensible reasons to choose more research. Specialized university equipment may make academia the fastest place to advance a technology. A real problem may support a modest business rather than venture-scale growth. Fifty Years’ own guidance makes room for those possibilities. Its useful proposition is that a scientist deserves help making the decision - before the startup, and all its obligations, exists.